Entries |
Document | Title | Date |
20080234378 | METHODS FOR THE PREPARATION AND FORMULATION OF L-CARNITINE VALPROATE SALTS - The present invention relates to methods for preparing an L-carnitine valproate salt and administering this compound to a subject in need of treatment with valproate. Pharmaceutical compositions are also provided that are useful therapies for the treatment of neurological, immunological, and viral-mediated disorders in warm-blooded mammals. | 09-25-2008 |
20080242727 | DIETARY COMPOSITIONS CONTAINING ALPHA AMINO N-BUTYRATE AND METHODS OF ENHANCING LEAN BODY MASS - A composition that may include branched chain amino acids, alpha amino n-Butyrate and/or alpha amino-n-valerate works synergistically to enhance lean body mass and prevent body mass breakdown. The composition may also be coupled with other agents to a) provide an increased level of amino acids and/or protein in the body's total pool or b) increase markers for protein translation or decrease markers of protein turnover. The composition may be administered in a variety of ways including capsules, tablets, powdered beverages, bars, gels or drinks. Increasing lean body mass is import to athletes looking to enhance performance, in the event of certain muscle wasting diseases, and to the general population that loses muscle mass as it ages. | 10-02-2008 |
20080242728 | PHENOLIC ACID SALTS OF GABAPENTIN IN SOLID DOSAGE FORMS AND METHODS OF USE - The present invention relates to pharmaceutical compositions of gabapentin tannate in solid dosage form, processes for production of those compositions and methods of use of those compositions. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid. | 10-02-2008 |
20080249174 | Animal Model for Studying Atherosclerotic Lesions - The present invention provides an animal model for atherosclerosis and a transgenic knockout animal. Methods for preventing and/or treating atherosclerosis are also provided. More specifically, the present invention provides methods of preventing and/or treating atherosclerosis by administering to a subject in need thereof an inhibitor of Serine palmitoyl-CoA transferase (SPT) or its subunit. | 10-09-2008 |
20080269332 | EYELASH ENHANCEMENT COMPOSITION AND METHOD OF TREATMENT - Effective enhancement of eyelash length and density can be obtained by topical applications of an active agent selected from a class of compounds consisting of synthetic prostaglandin agonists, polymers thereof and mixtures thereof preferably having the chemical formula of C | 10-30-2008 |
20080275120 | LEUCINE RICH COMPOSITION - The invention relates to the use of a composition comprising proteinaceous matter, said providing at least 24.0% of the energetic value of the composition (en %) and at least 12 wt. % based on proteinaceous matter leucine in the manufacture of a medicament for the treatment of insulin resistance and to a composition suitable for administration to a mammal comprising a protein fraction, a carbohydrate fraction and a lipid fraction, wherein the protein fraction provides at least 24.0 % (en %), the carbohydrate provides up to 46 en %, the lipid fraction provides up to 30 en % and wherein at least 12 wt. %, based on proteinaceous matter, of leucine. | 11-06-2008 |
20080275121 | N-HALOGENATED AMINO ACID FORMULATIONS AND METHODS FOR CLEANING AND DISINFECTION - The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a contact lens comprising an N-halogenated amino acid and a phase transfer agent. | 11-06-2008 |
20080275122 | N-HALOGENATED AMINO ACID FORMULATIONS WITH ANTI-INFLAMMATORY COMPOUNDS - The present invention relates to a formulation having antimicrobial activity comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification also describes methods for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. This specification further describes a method for treating respiratory infections comprising contacting the site of the respiratory infection with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a anti-inflammatory compound. | 11-06-2008 |
20080275123 | N-HALOGENATED AMINO ACID FORMULATIONS - The present invention relates to a method for treating a tissue infection comprising contacting the infected tissue with a pharmaceutically effective amount of a formulation comprising a N-halogenated amino acid and a phase transfer agent. This specification also describes a formulation having antimicrobial activity comprising a N-halogenated amino acid and a phase transfer agent. | 11-06-2008 |
20080275124 | POWDER OF AMINO ACIDS AND METHOD FOR PRODUCING THE SAME - Dry powders of amino acids which exhibit great oral meltability and solubility, may be produced by spray drying a hydrous liquid of amino acids to produce a powder of amino acids, where the hydrous liquid of amino acids is prepared into the form of microfine liquid droplets in the presence of trehalose for spray drying, to obtain a powder having a mean particle size of 0.1 μm to 15 μm, as well as granulating and drying during the spray drying or after the spray drying, to obtain a granulated powder having a mean particle size of 20 μm to 1,000 μm. | 11-06-2008 |
20080280981 | Tranexamic acid formulations - Disclosed are oral tranexamic acid formulations and methods of treatment therewith. | 11-13-2008 |
20080300307 | STABLE GABAPENTIN COMPOSITIONS - Stable compositions containing gabapentin compositions, methods of preparing such compositions, and methods of using such compositions. | 12-04-2008 |
20080312325 | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins - Methods of detecting and treating rapidly growing exogenous cells, such as | 12-18-2008 |
20090005449 | STRUCTURED COMPOSITIONS COMPRISING BETAINE - Provided are structured compositions comprising an anionic surfactant, a betaine, and a branched fatty alcohol, the composition having a Yield Stress from about 1 Pascal (Pa) to about 1500 Pa, as well as methods of making and using such compositions. | 01-01-2009 |
20090012168 | ADIPONECTION INDUCERS OR SECRETAGOGUES - The present invention discloses an adiponectin inducer or secretagogue which comprises an amino acid(s) selected from the group consisting of leucine, isoleucine, valine, methionine, cystein, alanine and a mixture(s) thereof, and a therapeutic agent of hypoadiponectinemia, hyperlipemia, hypertension or vascular disorders or an anti-inflammatory agent, which comprises the adiponectin inducer or secretagogue. | 01-08-2009 |
20090018196 | FOOD COMPOSITION COMPRISING AMINO ACIDS - The invention relates to a food composition comprising an amino acid part having at least the amino acids leucine, isoleucine, valine, threonine and lysine in an amount of from about 35 to 90 g/100 g of the total amount of the amino acid part as a method how to produce said food composition. The invention relates to different food products comprising said food composition. | 01-15-2009 |
20090042986 | Cosmetic liquid - A lotion is, ordinarily, slightly acidic, and moreover has been provided in such three kinds as an acidic lotion, an alkaline lotion, and a neutral lotion. The slight acidic lotion is ordinarily applied as being adapted to pH of skin and not having a particular stimulus thereto. Most of the acidic lotion is applied to make healthy pH of skin which ordinarily tends to become alkaline from Spring to Summer seasons. And alkaline lotion is applied to provide moisture to skin. These conventional types of lotions cause users to less feel moist and do not show an excellent effect of making soft skin. A cosmetic liquid having pH of 9 to 13 is now achieved. | 02-12-2009 |
20090048340 | GROWTH HORMONE SECRETION REGULATOR - The present invention provides a growth hormone secretion regulator or an anti-aging agent comprising aspartic acid and valine as active ingredients. The present invention also provides a pharmaceutical, food, nutritional supplement (supplement), or feeding stuff comprising the growth hormone secretion regulator or anti-aging agent. | 02-19-2009 |
20090048341 | Tranexamic acid formulations - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 02-19-2009 |
20090062391 | Use of a virucidal ointment in the nares for prevention of transmission and contraction of common colds - A novel method of preventing or inhibiting the contraction or communication of viruses which cause the common cold is proposed. Application of a virucidal ointment containing one or more organic acids (e.g. malic acid) with or without a surfactant (e.g. sodium C.sub.14-C.sub.16 olefin sulfonate) in a carrier agent (e.g. petrolatum) to the nares of well individuals will reduce the chance that they contract illness with the viruses which cause colds. Application of said ointment to the nares of individuals with a cold will reduce the chance they transmit the illness by reducing self-contamination of their hands when touching their nose. The ointment is most effective when applied with a clean applicator multiple times daily. | 03-05-2009 |
20090062392 | DEUTERIUM-ENRICHED GABAPENTIN - The present application describes deuterium-enriched gabapentin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
20090062393 | DEUTERIUM-ENRICHED PREGABALIN - The present application describes deuterium-enriched pregabalin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
20090069427 | ALPHA-2-DELTA LIGANDS FOR NON-RESTORATIVE SLEEP - The use of an alpha-2-delta ligand or a pharmaceutically acceptable salt thereof for the treatment of non-restorative sleep is disclosed. | 03-12-2009 |
20090082449 | Spray-Drying Process for Producing a Dry Caritine Powder or Granulate - A process for preparing a dry substantially pure and/or technical carnitine powder or granulate, from a substantially unpurified starting material containing a carnitine compound. | 03-26-2009 |
20090131524 | SIALIC ACID ABC TRANSPORTERS IN PROKARYOTES THERAPEUTIC TARGETS - This invention provides a novel bacterial sialic acid transporter that is a member of the family of ABC transporters. The transporter is a useful target for pharmaceuticals. | 05-21-2009 |
20090156676 | Organic salts of beta-alanine - The present invention relates to stable salts of β-alanine and an organic acid endowed with enhanced nutritional and/or therapeutical efficacy in respect to their individual effects and to solid compositions containing such salts, particularly suited to oral administration. A method of preparation is also provided. | 06-18-2009 |
20090156677 | Gabapentin-containing Solid Compositions and Process for Preparing the Same - The present invention provides a stabilized solid composition containing a 4-amino 3-substituted-butanoic acid derivative which can be obtained by incorporating a humectant as a stabilizer. | 06-18-2009 |
20090156678 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES - A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. | 06-18-2009 |
20090156679 | LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF - (2R)-2-Phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided. | 06-18-2009 |
20090170945 | PREGABALIN SALTS - Pregabalin besylate and pregabalin tosylate are pharmaceutically acceptable acid addition salts of pregabalin that are isolatable in solid state, particularly crystalline state, sufficiently soluble in water, and stable both in the solid state and in the solution. | 07-02-2009 |
20090170946 | Composition for Mold Remediation - An anti-fungal composition is disclosed and has enhanced microbiocidal activities for killing or inhibiting growth of live mold cells and spores. Further, the composition stops the production of mycotoxins associated with molds. Included among the molds vulnerable to the composition are black mold, | 07-02-2009 |
20090176881 | Unsaturated Alkyl Esters of 5-Aminolevulinic Acid, their Preparation and their Use - Disclosed are unsaturated alkyl esters of 5-aminovulinic acid of the following chemical formula 1, or pharmaceutically acceptable salts thereof, a method for preparing the same, and uses thereof. [Chemical Formula I] NH | 07-09-2009 |
20090176882 | GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME - Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin treatment. In addition to the foregoing, the gastric retentive gabapentin dosages forms also exhibit decreased blood plasma concentrations and increased bioavailability throughout the dosing regimen. | 07-09-2009 |
20090197956 | TREATMENT OF ACUTE OTITIS MEDIA WITH XYLITOL AND N-ACETYLCYSTEINE - The present invention relates to the discovery that the treatment of Acute Otis Media (AOM) can be accomplished by a synergistic combination of xylitol and N-acetylcysteine. The treatment with this combination shows that symptoms of AOM can be decreased and or treated to a greater degree than know with xylitol alone. The present invention includes both pharmaceutical compositions and methods of treatment. | 08-06-2009 |
20090203789 | Fast Dissolution Amino Acid Composition - The present invention relates to oral dosage formulations for the rapid release of amino acids. A rapid release is achieved through the process of milling whereby the milled amino acids are more readily bioavailable. | 08-13-2009 |
20090203790 | GAMMA-L-PGA PRODUCING MICROORGANISM, METHOD OF PRODUCING GAMMA-L-PGA USING THE MICROORGANISM, CROSSLINKED SUBSTANCE PRODUCED USING THE MICROORGANISM, AND EXTERNAL DERMAL AGENT PRODUCED USING THE MICROORGANISM - There are provided a microorganism characterized by producing poly-γ-L-glutamate with a molecular weight of 1,300,000 or greater and uniform optical purity under liquid culture conditions, a method of screening for the microorganism, a method of producing poly-γ-L-glutamate having large molecular weight by using the microorganism, and poly-γ-L-glutamate having an average molecular weight of 1,300,000 or greater. In addition, usages of these are provided. | 08-13-2009 |
20090203791 | NATEGLINIDE-CONTAINING PREPARATION - The present invention discloses, as a immediate-release preparation useful as an antidiabetic, a nateglinide-containing preparation comprising nateglinide as an active ingredient wherein the nateglinide is amorphous. | 08-13-2009 |
20090203792 | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS - A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α | 08-13-2009 |
20090209645 | METHODS FOR TREATING VASOMOTOR SYMPTOMS USING GABA ANALOGS IN A GASTRIC RETENTIVE DOSAGE FORM - Methods for treating vasomotor symptoms associated with menopause are described. | 08-20-2009 |
20090209646 | TRANEXAMIC ACID FORMULATIONS - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 08-20-2009 |
20090215898 | TRANEXAMIC ACID FORMULATIONS - Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith. | 08-27-2009 |
20090234009 | Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof - Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. | 09-17-2009 |
20090247635 | METHOD FOR TREATING ANAL PRURITIS AND OTHER PERIANAL DISORDERS - The invention relates to methods and compositions for the treatment of pruritis ani and other perianal disorders. There are currently few treatments for these conditions, many of which have significant side effects. The methods of the invention involve the administration, in a cream or lotion of pregabalin, an anti-epileptic agent that has pain relieving properties. This topical form of pregabalin may also include the addition of other agents such as immunomodulators, antibiotics or agents that enhance wound healing. This method may be useful as a new and safe treatment for pruritis ani, skin conditions and other anorectal disorders. Previous positive clinical experience suggests that this new treatment is promising for these disorders. | 10-01-2009 |
20090247636 | AGENT FOR SUPPRESSION OF GASTRIC EMPTYING COMPRISING 4-HYDROXYISOLEUCINE - The present invention aims to provide a more effective gastric emptying suppressant and food intake suppressant, wherein the solving means are a gastric emptying suppressant containing 4-hydroxyisoleucine or a salt thereof and a food intake suppressant containing 4-hydroxyisoleucine or a salt thereof. | 10-01-2009 |
20090253792 | ACTIVE AGENT DELIVERY SYSTEMS AND METHODS FOR PROTECTING AND ADMINISTERING ACTIVE AGENTS - The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions. | 10-08-2009 |
20090286880 | NOVEL PROCESS - The present invention relates to a novel process for the preparation of γ-amino acids, such as (±)-3-(aminomethyl)-5-methyl-hexanoic acid 1, which is a key intermediate in the preparation of the potent anticonvulsant pregabalin, (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid 2. | 11-19-2009 |
20090292021 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one substance having anti-ischemic effect, are disclosed. | 11-26-2009 |
20090298942 | ANIMAL COMPOSITION - The present invention relates to a composition which delivers an amount of leucine sufficient to enhance the learning ability of an animal. The present invention also relates to a food supplement for enhancing the learning ability of an animal and to methods for enhancing such learning ability. | 12-03-2009 |
20090312421 | GEL USEFUL FOR THE DELIVERY OF COSMETIC ACTIVE INGREDIENTS - It is described a gel, for cosmetic use, composed of a mixture of a polymer which forms a gel, a surfactant, and propionyl L-carnitine glycinate hydrochloride, useful for treating disturbances of the skin such as cellulite and wrinkles. | 12-17-2009 |
20090318555 | Treatment of Vertigo with Acetyl-L-Leucine - The use of acetyl-L-leucine and the pharmaceutically acceptable salts of same for the manufacture of a medicament for the treatment of vertigo and other balance disorders. Advantageously, the acetyl-L-leucine is a 100% mixture. | 12-24-2009 |
20090326071 | Method of feeding milk replacer with carnitine - A method of the present invention includes feeding a calf a milk replacer at an enhanced rate with carnitine. The method of the present invention enhances weight gain, starter intake and reduces weaning time. | 12-31-2009 |
20100016434 | Inhibitors of Egln3 Activity for the Treatment of Neurodegenerative Disorders - The present invention provides methods for preventing or reducing neuronal apoptosis, particularly wherein the apoptosis is associated with a neurodegenerative disorder in a subject. | 01-21-2010 |
20100035991 | AMIDE BASE SALTS OF SAHA AND POLYMORPHIS THEREOF - The present invention provides amine base salts of SAHA, polymorphs and pharmaceutical compositions thereof. The invention provides a method of treating cancer by administering the pharmaceutical composition. The invention also provides a crystalline composition comprising the amine base and SAHA. The invention also provides methods of obtaining the amine base salt and crystalline composition. | 02-11-2010 |
20100056632 | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG - A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided. | 03-04-2010 |
20100063148 | Pharmaceutical Combination - A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration. | 03-11-2010 |
20100081717 | Chiral Cyclic Beta-Amino Acids and their Derivatives, Pharmaceutical Compositions Containing Them and the Use of Such Compounds - The invention relates to chiral cyclic β-amino acids of Formula (I) and their salts formed with pharmaceutically acceptable acids or bases, wherein the main meanings of the substituents are as follows: R stands for C | 04-01-2010 |
20100081718 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS - The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salths thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain. | 04-01-2010 |
20100087534 | Use of a Photosensitizing Agent in the Treatment or Prevention of an Inflammation-Associated Disorder in the Gastrointestinal Tract of a Mammal - The present invention relates generally to the field of Photodynamic therapy (PDT) and more particularly to the use of a photosensitizing agent for the preparation of a medicament for the treatment or prevention of an inflammation-associated disorder in the gastrointestinal tract of a mammal, wherein the expression of pro-inflammatory markers in a tissue of said gastrointestinal tract is decreased after administering said photosensitizing agent to said tissue and exposing said tissue to a light having a wavelength absorbed by said photosensitizing agent. | 04-08-2010 |
20100105774 | ANTIDEPRESSANT - An antidepressant containing, as an active ingredient, at least one compound selected from a branched amino acid, a pharmaceutically acceptable salt thereof and a derivative thereof. | 04-29-2010 |
20100120915 | Antimicrobials and related methods - Compositions for antimicrobial, antibacterial, antiviral, fungicidal and sporicidal applications comprise a mixture of alkyl betaine and alkyl amine oxide components together with a protonating agent. The compositions are particularly effective in the treatment and elimination of microorganisms in planktonic cell form as well as in sessile cell form in biofilms. The compositions may be applied in the form of sprays and foams as well as in liquid forms, as a solution or as a balm, as the sole active ingredient or with other active ingredients together with carriers or diluents. | 05-13-2010 |
20100120916 | THERAPEUTIC AGENT AND DIAGNOSTIC AGENT FOR MITOCHONDRIAL DYSFUNCTION BRAIN DISEASES - To provide a therapeutic agent and a diagnostic agent for mitochondrial dysfunction brain diseases including cerebral infarction as a representative. | 05-13-2010 |
20100120917 | BUTYLAMMONIUM MODULATORS OF FATTY ACID TRANSPORT - The present invention relates to new butylammonium modulators of fatty acid transport, and/or removal of toxic acyl-CoA compounds, pharmaceutical compositions thereof, and methods of use thereof | 05-13-2010 |
20100137438 | ISOVALINE FOR TREATMENT OF PAIN - The invention provides for the use of isovaline or a pharmaceutically acceptable salt thereof for the treatment of Pain in a mammalian subject in some preferred embodiments, the invention provides for the treatment of acute and chronic Pain syndromes where other drug therapies have limited efficacy or unacceptable toxicity in said subject. | 06-03-2010 |
20100137439 | USE OF AMINOLEVULINIC ACID AND DERIVATIVES THEREOF - The invention provides the use of a photosensitiser which is 5-aminolevulinic acid (5-ALA) or a derivative (e.g. an ester) of 5-ALA, or a pharmaceutically acceptable salt thereof, in the manufacture of a composition for use in methods of photodynamic therapy (PDT) on an animal, wherein said PDT comprises: (a) administering to said animal a composition comprising said photosensitiser; and (b) photoactivating said photosensitiser, and wherein side-effects (e.g. pain and/or erythema) of said PDT are prevented or reduced by use of one or more of (i)-(iv): (i) said composition comprises said photosensitiser in a concentration of less than 10% wt (e.g. 0.5 to 8% wt), (ii) said composition is administered for less than 2 hours (e.g. 30 minutes to 90 minutes) prior to said photoactivation, (iii) said photoactivation is carried out with a light source having a fluence rate of less than 50 mW/cm | 06-03-2010 |
20100144879 | Antibiotic Compound - Fermentation of a nutrient medium with a eubacterium | 06-10-2010 |
20100144880 | AMINO ACID INHIBITORS OF PLASMIN - The present invention relates to new amino acid inhibitors of plasmin, pharmaceutical compositions thereof, and methods of use thereof | 06-10-2010 |
20100160436 | STABLE GABAPENTIN COMPOSITIONS - Stable compositions containing gabapentin compositions, methods of preparing such compositions, and methods of using such compositions. | 06-24-2010 |
20100197787 | Composition for Prevention of Hypoglycemic Condition - Disclosed is a composition for use in the prevention of a hypoglycemic condition, which comprises at least one compound selected from a branched amino acid, a pharmaceutically acceptable salt thereof and a derivative of the amino acid or salt as an active ingredient. The composition can promote the uptake of a saccharide into a brain cell to thereby prevent a hypoglycemic condition. | 08-05-2010 |
20100240754 | UNSATURATED FATTY AMINO ACID DERIVATIVES AND USE THEREOF IN DERMAL COSMETOLOGY - The present invention relates to drugs consisting of unsaturated fatty amino-acid derivatives of the general formula (I), and to their pharmaceutically acceptable acid addition salts, in which: X is oxygen or NH, Rn are independently hydrogen or a (C | 09-23-2010 |
20100267831 | Amino Acid-Containing Composition for Preventing or Remedying Decrease in the Skeletal Muscle of Aged People - The present invention provides an amino acid-containing composition for preventing or remedying a decrease in skeletal muscle mass of aged people, comprising L-leucine at a molar composition ratio of 35% or more with respect to total of essential amino acids. According to the invention, the protein anabolism of skeletal muscle can be promoted to prevent or remedy a decrease of the skeletal muscle mass of aged people. | 10-21-2010 |
20100280117 | Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders - Disclosed is a Menorrhagia Instrument and methods for the treatment of menstrual bleeding disorders. | 11-04-2010 |
20100280118 | Methods for treating substance dependence - The present invention provides methods for treating alcohol dependence and preventing relapse in subjects in protracted alcohol abstinence. Also provided are methods for treating subjects suffering from cannabis dependence. Typically, these methods entail administering to the subjects in need of treatment a therapeutically effective amount of gabapentin, an analog of gabapentin, or pharmaceutically acceptable salt thereof. | 11-04-2010 |
20100286273 | FOOD SUPPLEMENT - The present invention relates to the use of leucine, isoleucine and valine in the manufacture of a food supplement for improving the cognitive ability of a companion animal, a pet food supplement comprising leucine, isoleucine and valine and a method of improving the cognitive ability of an animal especially a companion animal. | 11-11-2010 |
20100292331 | Biomarkers for Prostate Cancer and Methods Using the Same - Methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early prediction of prostate cancer, disease grading, target identification/validation, and monitoring of drug efficacy are provided. Also provided are suites of small molecule entities as biomarkers for prostate cancer. | 11-18-2010 |
20100324139 | PROCESS TO PREGABALIN - The present invention relates to a novel method for the preparation of racemic pregabalin (1) or a single enantiomer thereof, (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid (2). | 12-23-2010 |
20110060045 | ANTI-DIABETIC CATARACT COMPOUNDS AND THEIR USES - The invention disclosed relates to the use of anti-glycation agents of formula (I), | 03-10-2011 |
20110065794 | Wrinkle-preventing and improving composition - A wrinkle-preventing and -improving composition comprising one or more than one compound selected from the group consisting of α-amino acid derivatives represented by the following general formula (1) and salts thereof: | 03-17-2011 |
20110082208 | THERAPIES FOR CANCER USING ISOTOPICALLY SUBSTITUTED LYSINE - Methods of treatment and substances for treatment of cancer may use or cause the creation of isotopically modified lysine at levels that do not occur naturally. | 04-07-2011 |
20110136909 | METHOD FOR SUPPRESSING EXCESSIVE APPETITE - Agents for the inhibition, suppression, or prevention of overeating include glutamic acid and/or at least one of its salts, as is or in a carrier or base, and have superior safety at a low price and further have a favorable flavor and are suited for long-term use. Such agents will amplify or sustain a sense of fullness and, further, are effective against appetite stimulation that arises regardless of a sense of fullness with respect to foods that are, for example, sweet or delicious, especially for a person who has a drive for thinness. | 06-09-2011 |
20110144204 | BUFFER SOLUTIONS HAVING SELECTIVE BACTERICIDAL ACTIVITY AGAINST GRAM NEGATIVE BACTERIA AND METHODS OF USING SAME - Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided. | 06-16-2011 |
20110178177 | TOPICAL FORMULATIONS FOR TREATMENT OF NEUROPATHY - Topical treatments for neuropathy are described. The treatments include topical formulations of NMDA antagonists and one additional active ingredient. In one example, the formulation includes ketamine and gabapentin for the treatment of a subject's neuropathy. These transdermal or topical compositions provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and can be administered to subjects to treat various neuropathies. | 07-21-2011 |
20110184065 | USE OF SPONGOSINE FOR THE TREATMENT OF PAIN - Use of spongosine (2-methoxyadenosine) as an analgesic, in particular for the treatment of hyperalgesia, is described. | 07-28-2011 |
20110218246 | METHODS OF TREATING NON-NOCICEPTIVE PAIN STATES WITH GASTRIC RETENTIVE GABAPENTIN - Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin treatment. In addition to the foregoing, the gastric retentive gabapentin dosages forms also exhibit decreased blood plasma concentrations and increased bioavailability throughout the dosing regimen. | 09-08-2011 |
20110230559 | Tranexamic Acid Formulations - Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith. | 09-22-2011 |
20110237670 | IMPROVEMENT OF NORMAL COGNITIVE FUNCTION - The present invention shows that administration of L-lysine enhances cognitive performance in healthy individuals directly and these improvements persist if L-lysine is continuously administrated. However, when administration is interrupted the cognitive performance returns to baseline. | 09-29-2011 |
20110263710 | Transepithelial methods of using gamma aminobutyric acid compositions for pain relief - Disclosed are methods for alleviating, relieving, inhibiting, and eliminating acute or chronic pain in a patient suffering from such pain by contacting epithelial tissue of the patient with exogenous GABA (gamma-amino butyric acid). | 10-27-2011 |
20110294885 | CONTROLLED-RELEASE PREGABALIN COMPOSITIONS - An orally-administrable controlled-release formulation, including pregabalin or a pharmaceutically acceptable salt of pregabalin and polycarbophil, as a controlled-release agent. | 12-01-2011 |
20110294886 | CONTROLLED-RELEASE TABLET FORMULATIONS OF PREGABALIN - A controlled-release tablet formulation which gels in the stomach, including pregabalin or a pharmaceutically acceptable salt thereof, and a complex of sodium alginate and calcium chloride, or calcium alginate, or a properly-proportioned mixture thereof as a controlled-release agent. | 12-01-2011 |
20110294887 | CONTROLLED-RELEASE SOLUTION FORMULATIONS OF PREGABALIN - A controlled-release oral solution formulation, which gels in the stomach, includes pregabalin or a pharmaceutically acceptable salt of pregabalin and a gelling agent. | 12-01-2011 |
20120022160 | COMPOSITION FOR EXTERNAL USE ON SKIN - It is intended to provide a cleansing cosmetic composition that quickly removes makeup from the skin, is easily applicable onto the skin without dripping from the hand or running on the face during application, and can freshen the skin because of being washed off thoroughly. The present invention provides a cleansing cosmetic composition comprising: (1) 1 to 15% by mass of silicone oil, (2) 1 to 15% by mass of volatile hydrocarbon oil, (3) 5 to 20% by mass of dihydric glycol, (4) 5 to 40% by mass of polyoxyethylene glyceryl fatty acid ester, and (5) 15 to 88% by mass of water, wherein the weight ratio between the silicone oil (1) and the volatile hydrocarbon oil (2) ((1)/(2)) falls within the range of 0.3 to 3 and the composition has a viscosity of 100 to 500 mPas at 25° C. | 01-26-2012 |
20120029081 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 02-02-2012 |
20120065265 | ALPHA-2-DELTA LIGANDS FOR NON-RESTORATIVE SLEEP - The use of an alpha-2-delta ligand or a pharmaceutically acceptable salt thereof for the treatment of non-restorative sleep is disclosed. | 03-15-2012 |
20120088832 | Anti-Adhesive Barrier Membrane Using Alginate and Hyaluronic Acid for Biomedical Applications - A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components. | 04-12-2012 |
20120095100 | USE OF A COMBINATION OF D-ASPARTIC AND L-ASPARTIC ACIDS OR SALTS THEREOF FOR THE TREATMENT OF MALE INFERTILITY - The present invention concerns the use of a combination consisting of D-aspartic and L-aspartic acids or L-aspartic acid used alone to stimulate the procreative activity in the man by increment of spermatozoon number and motility. | 04-19-2012 |
20120122984 | Methods of Treating Lipomas and Liposarcomas - The invention provides methods and compositions for treating lipomas and liposarcomas. The invention also provides methods for reducing white adipose tissue and weight in animals. | 05-17-2012 |
20120122985 | Tranexamic Acid Formulations - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 05-17-2012 |
20120142777 | PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN ALPHA-AMINOAMIDE AND ITS ANALGESIC USE - There is disclosed a pharmaceutical composition comprising gabapentin or an analogue thereof (pregabalin or tiagabine) and an α-aminoamide and its analgesic use. A synergistic effect of the respective analgesic activities without concomitant increase of side effects was observed. | 06-07-2012 |
20120157532 | Method Of Treating Or Preventing A Convulsive Disorder In A Patient In Need Thereof - The present invention relates to a method of treating or preventing a convulsive disorder in a patient in need thereof comprising administering said patient with a therapeutically effective amount of an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation once per day in the evening or at night. | 06-21-2012 |
20120157533 | Magnesium Compositions and Uses Thereof for Metabolic Disorders - A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided. | 06-21-2012 |
20120165408 | ORAL COMPOSITION FOR ALLEVIATING ROUGH SKIN - Provided is a stable and safe oral composition that acts on the barrier function of the skin for alleviating and/or preventing rough skin. An oral composition for alleviating rough skin and an oral composition for preventing rough skin are provided, the compositions containing at least one compound selected from the group consisting of D-glutamic acid and derivatives and/or salts thereof. Also provided are a pharmaceutical composition and/or a food composition containing the oral composition for alleviating rough skin or the oral composition for preventing rough skin. | 06-28-2012 |
20120172446 | L-SERINE TO BE USED AS A DRUG FOR PREVENTING AND/OR TREATING AN INFLAMMATORY RESPONSE OF THE SKIN - The invention relates to the use of L-serine as a drug for preventing and/or treating an inflammatory response of the skin caused by the overexpression and/or the overactivation of PAR2 receptors. | 07-05-2012 |
20120184619 | COMPOSITION FOR PROMOTING COLLAGEN PRODUCTION - Disclosed is a novel composition which has an effect on promoting production of collagen. The composition has high photostability and is free from side effects such as those of retinoids. Specifically disclosed is a composition for promoting collagen production which contains one or more compounds selected from the group consisting of D-aspartic acid, D-alanine, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving skin a condition. The skin condition may include but is not limited to photoaging and/or wrinkles. The composition may be used for an external preparation for the skin or food. The composition may be a composition for promoting type I collagen production. | 07-19-2012 |
20120184620 | ANTIOXIDANT COMPOSITION - Disclosed is a stable and safe antioxidant composition which can be used routinely. Specifically disclosed is an antioxidant composition which contains one or more compounds selected from the group consisting of D-aspartic acid, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving skin conditions. The skin conditions may include, but is not limited to, fine wrinkles, a rough skin, a dry skin, a skin cancer, a skin allergy, an inflammation of the skin and a photosensitive dermatosis. The composition may be used for an external preparation for the skin, a food, and a pharmaceutical product for cataract. | 07-19-2012 |
20120190745 | ORAL COMPOSITION FOR REDUCING WRINKLE FORMATION - Provided is a novel composition that acts to inhibit and/or ameliorate wrinkle formation, does not have adverse effects like those of retinoids, and is highly photostable. An oral composition for reducing wrinkle formation and an oral composition for preventing wrinkle formation are provided, the compositions containing at least one compound selected from the group consisting of D-glutamic acid and derivatives and/or salts thereof. Also provided are a pharmaceutical composition and a food composition containing the oral composition for reducing wrinkle formation or the oral composition for preventing wrinkle formation. | 07-26-2012 |
20120196935 | METHODS FOR DETECTING AUTODIGESTION - Materials and methods for detecting the early onset of shock and multi-organ failure by production of tissue breakdown products in biological samples (e.g., expired air). | 08-02-2012 |
20120232148 | Systems and Methods for Preventing Cancer and Treating Skin Lesions - Systems and methods of using a composition containing at least one or more amino acids for topical application to skin to prevent cancer and treat skin lesions. | 09-13-2012 |
20120232149 | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 09-13-2012 |
20120264825 | Amino Acid Perhydrates, Process for Their Preparation and Uses thereof - The invention provides compounds which are -amino acid hydrogen peroxide solvates, wherein the side chain of the -amino acid has no basic nitrogen. A process for preparing the compounds and uses thereof are also described. | 10-18-2012 |
20120283328 | PHOTOSENSITIZER COMPOSITION FOR TREATING SKIN DISORDERS - A composition comprising an active ingredient selected from the group of 5-aminolevulinic acid or a pharmaceutically acceptable salt or derivative thereof; and an aqueous carrier comprising at least one absorption enhancer, an anesthetic, hyaluronic acid and at least one acid selected from the group consisting of glycolic acid and lactic acid. The composition is useful in a photodynamic method of treating skin disorders. | 11-08-2012 |
20120289601 | Gastric Retained Gabapentin Dosage Form - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. | 11-15-2012 |
20120302640 | ORAL FORMULATIONS - The invention relates to a composition, in the form of a gel, comprising tranexamic acid for topical oral application to a tooth extraction site either before, during or after the tooth extraction to control dental bleeding, to treat or prevent alveolar osteitis, or to produce or maintain a blood clot. The composition may comprise additional components such as chlorhexidine, methyl cellulose, a sweetener, a flavouring agent (e.g. mint), and a preservative (e.g. potassium sorbate). | 11-29-2012 |
20120329873 | D-SERINE FOR THE TREATMENT OF VISUAL SYSTEM DISORDERS - The present invention relates to therapeutic methods using pharmaceutical compositions comprising one or a combination of co-agonists at the N-methyl-D-aspartate receptor for the treatment of visual system disorders. | 12-27-2012 |
20130012584 | Tranexamic Acid Formulations - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 01-10-2013 |
20130018100 | Tranexamic Acid Formulations - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 01-17-2013 |
20130030052 | COMPOSITIONS AND METHODS FOR THE SUSTAINED RELEASE OF BETA-ALANINE - Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine. Also provided is a dietary supplement formulated, for example, as a solid food product, an edible suspension, liquid or semi-liquid as described herein. | 01-31-2013 |
20130059913 | COMPOSITION FOR AMELIORATION OF HYPOALBUMINEMIA - The present invention is directed to a composition for ameliorating hypoalbuminemia containing a branched-chain amino acid(s) as an active ingredient(s), wherein the composition contains leucine and/or isoleucine as the active ingredient(s) and does not contain valine. As the above branched-chain amino acid(s), leucine and isoleucine are preferably contained. The mass ratio of leucine to isoleucine described above is preferably from 0.1 to 10. As the above branched-chain amino acid(s), either leucine or isoleucine alone may be contained. The present invention is suitably used as an infusion formulation, an oral formulation or a food or drink. | 03-07-2013 |
20130065960 | METHOD FOR PRODUCING POWDER MIXTURE - There is provided a method for producing a powder mixture containing an alkali metal salt that exhibits basicity in an aqueous solution (component (A)); at least one type of metal salt selected from the salts of copper, manganese, iron, cobalt and zinc (component (B)); and a compound represented by the following general formula (1) (component (C)), including spraying and mixing an aqueous solution of metal which is an aqueous solution of the aforementioned component (B) with a powder of the aforementioned component (A), and then mixing a powder of the aforementioned component (C) therewith. According to the present invention, it is possible to provide a method for producing a powder mixture which can easily produce a powder mixture that exhibits excellent solubility in water even when containing a basic alkali metal salt and a metal salt: | 03-14-2013 |
20130079410 | OIL-IN-WATER TYPE EMULSION SKIN COSMETIC - An oil-in-water type emulsion skin cosmetic which can be spread on skin easily. The formulation can contain glycerin at a high concentration or a formulation containing a combination of glycerin and an acrylamide-type thickening agent without the sticky effect. The skin cosmetic is characterized by comprising (A) a D-amino acid or a derivative or salt thereof, (B) a homopolymer, a copolymer or a crosspolymer containing at least one component selected from 2-acrylamide-2-methylpropanesulfonic acid, acrylic acid and derivatives thereof as a constituent unit, (C) an ester oil with an IOB value of 0.2 to 0.6, and (D) glycerin. | 03-28-2013 |
20130096198 | Tranexamic Acid Formulations - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 04-18-2013 |
20130102675 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 04-25-2013 |
20130116320 | GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME - Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin treatment. In addition to the foregoing, the gastric retentive gabapentin dosages forms also exhibit decreased blood plasma concentrations and increased bioavailability throughout the dosing regimen. | 05-09-2013 |
20130116321 | COMPOSITION CONTAINING SERINE AS AN ACTIVE INGREDIENT FOR THE PREVENTION AND TREATMENT OF FATTY LIVER DISEASES, AND THE USE THEREOF - The present invention is related to a composition comprising a serine as an active ingredient for treating or preventing fatty liver diseases. The inventive compound significantly inhibits the SREBP-1 transcription activity involved in lipid synthesis and reduced the fatty liver formation through various in vitro test and in vivo test therefore it can be useful in the prevention and treatment of the fatty liver diseases as a medicament or health functional food. | 05-09-2013 |
20130158121 | METHODS FOR TREATING VASOMOTOR SYMPTOMS USING GABA ANALOGS IN A GASTRIC RETENTIVE DOSAGE FORM - Methods for treating vasomotor symptoms associated with menopause are described. | 06-20-2013 |
20130190400 | METHOD FOR PRODUCING GAMMA-AMINOBUTYRIC ACID AND FOOD PRODUCED THEREBY - The embodiment of invention provides a method for producing γ-aminobutyric acid, including the steps of providing a medium including | 07-25-2013 |
20130190401 | VETERINARY DERMATOLOGIC COMPOSITION - This invention relates to the use of an active compound selected from the group comprising a sphingoid base, a sphingoid base derivative or a mixture of two or more these compounds for manufacturing a cosmetic composition suitable for topical application with animals having an at least partly fur covered skin for maintaining and/or repairing the keratoseborrheaic condition of the skin and/or fur. | 07-25-2013 |
20130245120 | INJECTABLE IBUPROFEN FORMULATION - The present invention provides a pharmaceutical composition comprising an aqueous solution of an ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition. The invention further provides a method of treating a condition chosen from pain, inflammation, fever, and/or patent ductus arteriosis, comprising administering to a patient in need thereof an effective amount of an aqueous solution a ibuprofen solubilizing agent and ibuprofen, the ibuprofen solubilizing agent being in an effective amount such that the ibuprofen in the solution remains soluble at concentrations from 100 mg/mL to 5 mg/mL without undergoing a phase transition, as well as a method for manufacturing the composition. | 09-19-2013 |
20130261184 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF PREGABALIN - A controlled release pharmaceutical composition which comprises therapeutically effective amount of pregabalin or salts thereof as active ingredient, a hydrophobic release controlling agent(s) and optionally other pharmaceutically acceptable excipients thereof. | 10-03-2013 |
20130296429 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF - Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate. | 11-07-2013 |
20130303618 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 11-14-2013 |
20140011878 | HIGH-DOSE GLYCINE AS A TREATMENT FOR OBSESSIVE-COMPULSIVE DISORDER AND OBSESSIVE-COMPULSIVE SPECTRUM DISORDERS - The present invention provides for a method of treating OCD or an Obsessive-Compulsive Spectrum Disorder (OCSD), such as BDD or ADHD, using a high-dose glycine treatment. | 01-09-2014 |
20140039054 | ORAL COMBINATION DRUG FORMULATION COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND A COMPLEMENTARY LOW DOSE OF TRANEXAMIC ACID FOR THE TREATMENT OF MENSTRUAL PAIN ACCOMPANIED WITH EXCESSIVE MENSTRUAL BLOOD LOSS - A method for relieving menstrual pain and reducing menstrual blood loss in a female is provided. The method comprises administering to the female an oral combination drug formulation comprising a first therapeutically effective dose of a non-steroidal anti-inflammatory drug (NSAID) and a second complementary low dose of tranexamic acid, wherein the NSAID is formulated to relieve the menstrual pain and to reduce a volume of menstrual blood loss of the female, wherein the dose of tranexamic acid ranges from 50 mg to 425 mg per oral combination drug formulation. | 02-06-2014 |
20140100282 | INTRANASAL ADMINISTRATION OF PHARMACEUTICAL AGENTS FOR TREATMENT OF NEUROLOGICAL DISEASES - Pharmaceutical formulations for treating neurological diseases are described, wherein the formulations comprise a pharmaceutically active agent-transport moiety complex. The formulations are suitable for administration via an intranasal route. Neurological diseases and conditions are associated with reduced brain insulin signaling (i.e., CNS insulin insensitivity), reduced dopaminergic signaling, reduced serotonergic signaling, reduced cholinergic signaling, or reduced GABAergic signaling, and include Alzheimer's disease, Parkinson's disease, epilepsy, neuropathic pain, fibromyalgia, post-herpetic neuralgia, insomnia, or anxiety. Neurological diseases also include cancers of the central nervous system (CNS). | 04-10-2014 |
20140135395 | GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME - Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin treatment. In addition to the foregoing, the gastric retentive gabapentin dosages forms also exhibit decreased blood plasma concentrations and increased bioavailability throughout the dosing regimen. | 05-15-2014 |
20140163103 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 06-12-2014 |
20140194514 | TOPICAL FORMULATIONS - Topical treatments for neuropathy are described. The treatments include topical formulations of NMDA antagonists and one additional active ingredient. In one example, the formulation includes ketamine and gabapentin for the treatment of a subject's neuropathy. These transdermal or topical compositions provide a surprising degree of effective relief from the symptoms of peripheral neuropathy and can be administered to subjects to treat various neuropathies. | 07-10-2014 |
20140243412 | PROCESS FOR PREPARATION OF PREGABALIN - Aspects of the present invention relate to improved process for preparation of (R)(−)-3-(carbamoylmethyl)-5-methylhexanoic acid (R-CMHA) of the formula (II) or its pharmaceutically acceptable salts in the presence of a lewis acid, process for preparation of pregabalin using R-CMHA of the formula (II) or its pharmaceutically acceptable salts prepared according to the present invention and process for preparation of pregabalin with low amount of undesired impurity. | 08-28-2014 |
20140275256 | Transepithelial Methods Of Using Gamma Aminobutyric Acid Compositions For Pain Relief - Disclosed are methods for alleviating, relieving, inhibiting, and eliminating acute or chronic pain in a patient suffering from such pain by contacting epithelial tissue of the patient with exogenous GABA (gamma-amino butyric acid). | 09-18-2014 |
20140309305 | HYPERTENSION REDUCING COMPOSITION - A composition effective to relax smooth muscles in an individual in an altered state is described. The composition includes a dosage of GABA or GABA-a analogue, and a dosage of at least one of an ACE inhibitor and an ARB combined with the dosage of GABA or GABA-a analogue into a deliverable form. | 10-16-2014 |
20140309306 | COMPOSITION FOR AMELIORATION OF HYPOALBUMINEMIA - The present invention is directed to a composition for ameliorating hypoalbuminemia containing a branched-chain amino acid(s) as an active ingredient(s), wherein the composition contains leucine and/or isoleucine as the active ingredient(s) and does not contain valine. As the above branched-chain amino acid(s), leucine and isoleucine are preferably contained. The mass ratio of leucine to isoleucine described above is preferably from 0.1 to 10. As the above branched-chain amino acid(s), either leucine or isoleucine alone may be contained. The present invention is suitably used as an infusion formulation, an oral formulation or a food or drink. | 10-16-2014 |
20140316004 | TREATMENT OF POULTRY FOR REDUCING THE FEED CONVERSION RATE OR FOR REDUCING THE INCIDENCE OF ASCITES - The invention relates to a method for the non-therapeutic treatment of poultry for the purpose of reducing the conversion rate of the feed used to raise the poultry. The treatment includes orally administering at least one glycine compound to the poultry, which glycine compound corresponds to the following formula (I) or to a salt thereof: | 10-23-2014 |
20140336256 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS - The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride salt is expressly contemplated. | 11-13-2014 |
20140343147 | NUTRITIONAL SUPPLEMENT FOR THE ENHANCEMENT OF MUSCLE PERFORMANCE AND RECOVERY AND METHODS OF USE THEREOF - Described herein are nutritional supplements containing α-hydroxy-isocaproic acid and aspartic acid (e.g., DAA) and their methods of use in enhancing muscle performance and/or recovery after exercise. The nutritional supplements can be used to enhance muscle building and lean body mass, enhance muscle and physical performance, enhance recovery, and prevent catabolism (muscle atrophy or wasting) when administered to a mammalian subject. | 11-20-2014 |
20140343148 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR IDIOPATHIC INFLAMMATORY MYOPATHIES - Administration of isoleucine, leucine and valine is effective for the prophylaxis and/or therapy of idiopathic inflammatory myopathy or idiopathic inflammatory myopathy associated with steroid-induced myopathy that develops during the course of treatment. This method is effective for the prophylaxis and/or therapy of idiopathic inflammatory myopathy or idiopathic inflammatory myopathy associated with steroid-induced myopathy that develops during the course of treatment. | 11-20-2014 |
20140378545 | PREGABALIN GR TABLETS - The present invention relates to a gastroretentive tablet comprising pregabalin, an acrylic acid polymer, one or more swellable polymers, and other pharmaceutically acceptable excipients. It further relates to a process for the preparation of same. | 12-25-2014 |
20150018418 | COMPOSITIONS AND METHODS FOR PROLONGING PREGNANCY - Provided are compositions and methods for use for prolonging pregnancy. The methods involve administering to an individual in need thereof an effective amount of a composition that contains a compound which is capable of specifically binding to an alpha2delta subunit of a voltage-gated calcium channel, such as gabapentin, pregabalin, and pharmaceutically acceptable salts and prodrugs thereof The composition is administered such that pregnancy is prolonged to by reducing, stopping, preventing and/or preventing recurrence of preterm labor during a human pregnancy. Also provides are articles of manufacture that have packaging containing one or a combination of compounds that are capable of specifically binding an alpha2delta subunit of a voltage-gated calcium channel. The compound is provided in an amount sufficient for alleviating and/or preventing preterm labor in a pregnant human female. The packaging comprises printed material, the printed material providing an indication that the pharmaceutical composition is for use in the alleviating or preventing of preterm labor and/or for prolonging pregnancy. | 01-15-2015 |
20150018419 | TRANEXAMIC ACID FORMULATIONS - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 01-15-2015 |
20150025146 | GASTRORETENTIVE TABLETS - The present invention relates to a gastroretentive tablet comprising pregabalin, at least one swellable polymer, and other pharmaceutically acceptable excipients. It further relates to a process for the preparation of same. | 01-22-2015 |
20150057354 | METHOD OF MAINTAINING OR IMPROVING TACTICAL PERFORMANCE AND COGNITIVE FUNCTION THROUGH DIETARY SUPPLEMENTATION - The present invention provides methods of maintaining or improving tactical performance and/or psychomotor performance, wherein the free amino acid beta-alanine, or a salt or ester thereof, is administered to an individual as a human dietary supplement over a period of time in an amount effective to maintain or improve tactical performance and/or psychomotor performance under normally stressful and/or fatiguing high intensity physical activity. | 02-26-2015 |
20150094371 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 04-02-2015 |
20150126603 | TREATMENT OF POULTRY, PIGS OR FISH FOR REDUCING THE FEED CONVERSION RATIO OR INCREASING THEIR BODYWEIGHT GAIN - The invention relates to a method for the non-therapeutic treatment of animals selected from the group consisting of poultry, pigs and fish. The treatment comprises orally administering at least one β-alanine compound to the animals in an amount of between 2 and 55 mmol/kg dry weight of said feed for the treatment of poultry and fish and between 2 and 25 mmol/kg dry weight of said feed for the treatment of pigs. These amounts of the β-alanine compound are used for reducing the conversion ratio or for in creasing the bodyweight gain of the animals. The β-alanine compound is in particular β-alanine. In prior art methods higher amounts were used resulting also in a reduction of the feed conversion ratio but this to the detriment of the bodyweight gain. | 05-07-2015 |
20150141512 | POLYMER-BASED DIALYSATE - Embodiments described herein provide a dialysate comprising a polyglycerol. The polyglycerol may be of a molecular weight between about 0.15 kDa and about 60 kDa. Also provided herein is the use of the dialysate as a diffusion agent and as an osmotic agent. | 05-21-2015 |
20150290127 | TRANEXAMIC ACID FORMULATIONS - Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith. | 10-15-2015 |
20150290157 | TRANEXAMIC ACID FORMULATIONS - Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith. | 10-15-2015 |
20150307442 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF - The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders. | 10-29-2015 |
20150321995 | Crystalline particles of glutamic acid N,N-diacetic acid - The invention relates to glutamic acid N,N-diacetic acid (GLDA) of the formula GLDA-Y | 11-12-2015 |
20150327575 | METHODS FOR IMPROVING THE CONDITION OF HAIR IN NON-HUMAN ANIMALS - The present invention involves methods for improving the quality of the hair of a non-human animal and for increasing the 18-methyleicosanoic acid content of the hair of a non-human animal comprising feeding to the animal an edible composition comprising an effective amount of an amino acid selected from the group comprising isoleucine, threonine, and mixtures thereof. | 11-19-2015 |
20150342915 | INSTANTIZED PRODUCT AND METHODS - This disclosure describes, in one aspect, a composition that generally includes a hydrophobic biologically active material and an emulsifier coating at least a portion of the hydrophobic biologically active material. In some embodiments, the hydrophobic biologically active material can include an amino acid or a combination of amino acids. In certain embodiments, the amino acids can be leucine, isoleucine, valine, or any combination of two or more of those amino acids. In another aspect, this disclosure describes a composition comprising a liquid and an emulsifier-coated hydrophobic biologically active material. In some embodiments, the liquid and the emulsifier-coated hydrophobic biologically active material are mixed. | 12-03-2015 |
20150352066 | Solid Pharmaceutical Compositions Containing Pregabalin - A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone. | 12-10-2015 |
20150353475 | Crystalline particles of salts of glutamic acid N,N-diacetic acid - The invention relates to a salt of glutamic acid-N,N-diacetic acid (GLDA) of the formula GLDA-Y | 12-10-2015 |
20150359767 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY - A compounded transdermal cream for topical administration of a compounded therapy includes a nerve depressant such as gabapentin in an amount between approximately 5% and 15% by weight of the transdermal cream, an NSAID (Non-Steroidal Anti-Inflammatory Drug) such as nabumetone in an amount between approximately 5% and approximately 25% by weight of the transdermal cream, a tricyclic antidepressant such as amitriptyline in an amount between approximately 0.5% and approximately 4% by weight of the transdermal cream, a local anesthetic such as lidocaine and prilocaine in an amount between approximately 1% and approximately 7% by weight of the transdermal cream, and dimethyl sulfoxide (DMSO). | 12-17-2015 |
20150359768 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY - A compounded transdermal cream for the topical administration of a compounded therapy includes a first active agent selected from the group consisting of nabumetone in an amount between approximately 5.0% and approximately 25% by weight of the transdermal cream and amitriptyline in an amount between approximately 0.5% and approximately 4.0% by weight of the transdermal cream; a second active agent comprising a nerve depressant in an amount between approximately 5.0% and 15.0% by weight of the transdermal cream, wherein the nerve depressant is gabapentin; a third active agent comprising a local anesthetic in an amount between approximately 1.0% and approximately 7.0% by weight of the transdermal cream, wherein the local anesthetic comprises lidocaine and prilocaine; and dimethyl sulfoxide (DMSO). | 12-17-2015 |
20150359769 | METHOD FOR DECREASING SKELETAL MUSCLE DAMAGE AND/OR OXIDATIVE STRESS IN MAMMALS - A method for reducing muscle damage and/or oxidative stress in active mammals as disclosed. In one embodiment, the mammals are administered a carnitine supplement. The L-carnitine supplement may be administered without any other pharmaceutical or drug products. After physical activity the L-carnitine supplement can lower myoglobin, TBARS, and creatine kinase in the bloodstream. | 12-17-2015 |
20160031798 | 2-AMINO-3-METHYL-HEX-5-ENOIC ACID AND ITS USE IN THE PRODCTION OF PEPTIDES SUCH AS BACITRACINS - The present invention concerns 2-amino-3-mmethyl-hex-5-enoic acid, its use for the production of peptides such as bacitracins and a method for producing it. | 02-04-2016 |
20160058726 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRAIN INJURY - Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury. | 03-03-2016 |
20160067200 | USES OF 6-AMINOHEXANOIC ACID TO MANAGE BLEEDING CONDITIONS - This disclosure relates to the use of EACA (6-aminohexanoic acid) as an antifibrinolytic for the prevention of thrombocytopenic bleeds. In certain embodiment, the disclosure relates to methods of preventing bleeding in patients with thrombocytopenia resulting from hematological malignancies by administering 6-aminohexanoic acid, salts, or prodrugs thereof prophylactically to a subject in need thereof. In certain embodiments, subjects with stable chronic thrombocytopenia previously managed with platelet transfusion represent a selected group of patients that benefit from prophylaxis. | 03-10-2016 |
20160081897 | Triclosan-Free Antibacterial Soap - Disclosed herein is an antibacterial cleansing composition. The cleansing composition is free of triclosan and comprises lactic acid/lactate, at least one C2 to C3 alcohol, and glutamate diacetate. Lactic acid/lactate is present in the composition in an amount of about 5 weight percent (wt %) to about 15 wt %, based on the total weight of the composition. The C2 to C3 alcohol is present in an amount of about 1 wt % to about 20 wt %, based on the total weight of the composition. Glutamate diacetate is present in an amount of about 0.05 wt % to about 5 wt %. The pH of the composition is about 4 to about 5. The triclosan-free cleansing composition according to the invention has superior antibacterial activity that surpasses comparable triclosan-free formulations that do not contain glutamate diacetate. | 03-24-2016 |
20160090353 | PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF - The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders. | 03-31-2016 |
20160120830 | Autoimmune-Induced Glutamatergic Receptor Dysfunction Methods and Treatments - This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. This invention also provides a method of mitigating the severity of, mitigating the pathogenesis of, lowering the incidence of or treating a disease associated with NMDAR antibody production, said method comprising administering an agent, which is an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. | 05-05-2016 |
20160120831 | INCREASE OF PROTEIN SYNTHESIS AMELIORATES SYNAPTOPATHY-RELATED NEUROLOGICAL DISORDERS - Disclosed herein is a method for increasing the dendritic spine formation or dendritic spine density in a subject, whom is affected by a dendritic spine defect caused by the impairment in neurofibromin (NF1 protein), valosin-containing protein (VCP), atlastin-1 (ATL1), or superoxide dismutase 1 (SOD1). Accordingly, also disclosed herein is a method for treating a subject having or suspected of having a synaptopathy caused by the impairment in NF1, VCP, ATL1, or SOD1. | 05-05-2016 |
20160128958 | Ornithine Aminotransferase Inhibition with GABA Analogues for Treatment of Hepatocellular Carcinoma - Therapeutic methods relating to the use of GABA-AT inhibitor compounds for the treatment of hepatocellular carcinoma. | 05-12-2016 |
20160151316 | METHOD OF TREATING TOURETTE'S DISORDER WITH GABA-AMINOTRANSFERASE INACTIVATORS | 06-02-2016 |
20160184250 | ENHANCER OF SURVIVAL OF TRANSPLANTED ORGAN - The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate. | 06-30-2016 |
20160250147 | Solid Pharmaceutical Compositions Containing Pregabalin | 09-01-2016 |
20190142778 | TREATMENT FOR MYOPIA | 05-16-2019 |